196 related articles for article (PubMed ID: 27866277)
21. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A
Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817
[TBL] [Abstract][Full Text] [Related]
22. Novel management strategies for idiopathic pulmonary fibrosis.
Ahmad K; Nathan SD
Expert Rev Respir Med; 2018 Oct; 12(10):831-842. PubMed ID: 30136607
[TBL] [Abstract][Full Text] [Related]
23. Etiology and treatment of cough in idiopathic pulmonary fibrosis.
Vigeland CL; Hughes AH; Horton MR
Respir Med; 2017 Feb; 123():98-104. PubMed ID: 28137504
[TBL] [Abstract][Full Text] [Related]
24. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.
Wu N; Yu YF; Chuang CC; Wang R; Benjamin NN; Coultas DB
J Med Econ; 2015 Apr; 18(4):249-57. PubMed ID: 25428658
[TBL] [Abstract][Full Text] [Related]
25. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.
Raghu G; Amatto VC; Behr J; Stowasser S
Eur Respir J; 2015 Oct; 46(4):1113-30. PubMed ID: 26424523
[TBL] [Abstract][Full Text] [Related]
26. Idiopathic pulmonary fibrosis: the role of the pharmacy benefit manager in providing access to effective, high-value care.
Morrow TJ
Am J Manag Care; 2015 Oct; 21(14 Suppl):s294-301. PubMed ID: 26788616
[TBL] [Abstract][Full Text] [Related]
27. Dyspnea in idiopathic pulmonary fibrosis: a systematic review.
Ryerson CJ; Donesky D; Pantilat SZ; Collard HR
J Pain Symptom Manage; 2012 Apr; 43(4):771-82. PubMed ID: 22285287
[TBL] [Abstract][Full Text] [Related]
28. Optimizing quality of life in patients with idiopathic pulmonary fibrosis.
van Manen MJ; Geelhoed JJ; Tak NC; Wijsenbeek MS
Ther Adv Respir Dis; 2017 Mar; 11(3):157-169. PubMed ID: 28134007
[TBL] [Abstract][Full Text] [Related]
29. Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study.
Cottin V; Schmidt A; Catella L; Porte F; Fernandez-Montoya C; Le Lay K; Bénard S
PLoS One; 2017; 12(1):e0166462. PubMed ID: 28099456
[TBL] [Abstract][Full Text] [Related]
30. How does comorbidity influence survival in idiopathic pulmonary fibrosis?
Hyldgaard C; Hilberg O; Bendstrup E
Respir Med; 2014 Apr; 108(4):647-53. PubMed ID: 24529739
[TBL] [Abstract][Full Text] [Related]
31. Respiratory comorbidities and risk of mortality in hospitalized patients with idiopathic pulmonary fibrosis.
Oda K; Yatera K; Fujino Y; Kido T; Hanaka T; Sennari K; Fushimi K; Matsuda S; Mukae H
Respir Investig; 2018 Jan; 56(1):64-71. PubMed ID: 29325684
[TBL] [Abstract][Full Text] [Related]
32. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
33. Patients' and healthcare professionals' perspectives on the idiopathic pulmonary fibrosis care journey: a qualitative study.
Delameillieure A; Dobbels F; Vandekerkhof S; Wuyts WA
BMC Pulm Med; 2021 Mar; 21(1):93. PubMed ID: 33736646
[TBL] [Abstract][Full Text] [Related]
34. The clinical impact of major comorbidities on idiopathic pulmonary fibrosis.
Suzuki A; Kondoh Y
Respir Investig; 2017 Mar; 55(2):94-103. PubMed ID: 28274539
[TBL] [Abstract][Full Text] [Related]
35. Idiopathic pulmonary fibrosis: phenotypes and comorbidities.
Fell CD
Clin Chest Med; 2012 Mar; 33(1):51-7. PubMed ID: 22365245
[TBL] [Abstract][Full Text] [Related]
36. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
37. Management of idiopathic pulmonary fibrosis.
Cerri S; Spagnolo P; Luppi F; Richeldi L
Clin Chest Med; 2012 Mar; 33(1):85-94. PubMed ID: 22365248
[TBL] [Abstract][Full Text] [Related]
38. Idiopathic pulmonary fibrosis: evolving concepts.
Ryu JH; Moua T; Daniels CE; Hartman TE; Yi ES; Utz JP; Limper AH
Mayo Clin Proc; 2014 Aug; 89(8):1130-42. PubMed ID: 24867394
[TBL] [Abstract][Full Text] [Related]
39. Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis.
Serrano-Mollar A; Gay-Jordi G; Guillamat-Prats R; Closa D; Hernandez-Gonzalez F; Marin P; Burgos F; Martorell J; Sánchez M; Arguis P; Soy D; Bayas JM; Ramirez J; Tetley TD; Molins L; de la Bellacasa JP; Rodríguez-Villar C; Rovira I; Fiblà JJ; Xaubet A;
Chest; 2016 Sep; 150(3):533-43. PubMed ID: 27020420
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic pulmonary fibrosis is associated with increased impedance measures of reflux compared to non-fibrotic disease among pre-lung transplant patients.
Gavini S; Finn RT; Lo WK; Goldberg HJ; Burakoff R; Feldman N; Chan WW
Neurogastroenterol Motil; 2015 Sep; 27(9):1326-32. PubMed ID: 26176338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
